Gsa Capital Partners LLP Halozyme Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 3,790 shares of HALO stock, worth $204,508. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,790Holding current value
$204,508% of portfolio
0.02%Shares
17 transactions
Others Institutions Holding HALO
# of Institutions
536Shares Held
124MCall Options Held
177KPut Options Held
167K-
Black Rock Inc. New York, NY17.6MShares$951 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$696 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$358 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$219 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$184 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.52B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...